PolyVascular
Cindy Clague is a seasoned professional in the medical device industry with extensive experience in research and development, particularly in cardiovascular technologies. As the VP of R&D at PolyVascular since December 2022, Cindy leads the development of a groundbreaking non-surgical heart valve for children with congenital heart disease. Prior to this role, as Chief Research Scientist at NirvaMed, Inc. from July 2020 to June 2023, Cindy focused on preclinical research for a novel treatment designed to significantly reduce heart muscle damage from massive heart attacks. In earlier positions, Cindy served as Director of Emerging Technologies at Resolution Medical and held various roles at Medtronic, advancing coronary and structural heart therapies through leadership of research teams and collaboration with external experts. Cindy holds a PhD in Biomedical Engineering from the University of Minnesota and a BS in Mechanical Engineering from Northwestern University.
This person is not in any teams
PolyVascular
Children born with congenital heart defects may require frequent surgeries that prevent them from living their lives to the fullest. PolyVascular provides the only non-surgical pulmonary valve and delivery system suitable for children as young as 2 years old. Our minimally invasive valve reduces the need for open heart surgery and enables kids to enjoy a healthy, normal lifestyle. Current animal tissue valves often cause endocarditis, while human tissue grafts may sensitize the child's immune system. We address these limitations with our biocompatible, durable, polymer-based valve. Our valve, provided with an-easy-to-use delivery system for clinicians, is easy to manufacture at any size.